EA201691438A1 - Антитело, которое связывается с erbb-2 и erbb-3 - Google Patents
Антитело, которое связывается с erbb-2 и erbb-3Info
- Publication number
- EA201691438A1 EA201691438A1 EA201691438A EA201691438A EA201691438A1 EA 201691438 A1 EA201691438 A1 EA 201691438A1 EA 201691438 A EA201691438 A EA 201691438A EA 201691438 A EA201691438 A EA 201691438A EA 201691438 A1 EA201691438 A1 EA 201691438A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- erbb
- antibodies
- antigen
- binds
- treatment
- Prior art date
Links
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 5
- 101150029707 ERBB2 gene Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000056372 ErbB-3 Receptor Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится, среди прочего, к антителам, содержащим первый антигенсвязывающий сайт, который связывается с ErbB-2, и второй антигенсвязывающий сайт, который связывается с ErbB-3. Антитела обычно обладают способностью снижать индуцируемую лигандом функцию рецептора ErbB-3 на ErbB-2- и ErbB-3-положительной клетке. Также описаны способы лечения и применение антител в визуализации и в лечении субъектов с ErbB-2-, ErbB-3- или ErbB-2/3-положительной опухолью.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14157360 | 2014-02-28 | ||
EP14167066 | 2014-05-05 | ||
PCT/NL2015/050125 WO2015130173A1 (en) | 2014-02-28 | 2015-02-27 | Antibody that binds erbb-2 and erbb-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201691438A1 true EA201691438A1 (ru) | 2017-04-28 |
Family
ID=52633560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691438A EA201691438A1 (ru) | 2014-02-28 | 2015-02-27 | Антитело, которое связывается с erbb-2 и erbb-3 |
Country Status (22)
Country | Link |
---|---|
US (5) | US11279770B2 (ru) |
EP (3) | EP3470435B1 (ru) |
JP (4) | JP6967853B2 (ru) |
KR (2) | KR20160145560A (ru) |
CN (1) | CN106459212B (ru) |
AU (2) | AU2015223567B2 (ru) |
CA (1) | CA2941077A1 (ru) |
CL (1) | CL2016002156A1 (ru) |
CY (1) | CY1123556T1 (ru) |
DK (1) | DK3110849T3 (ru) |
EA (1) | EA201691438A1 (ru) |
ES (2) | ES2826774T3 (ru) |
HR (1) | HRP20201837T1 (ru) |
HU (1) | HUE052506T2 (ru) |
IL (2) | IL301147A (ru) |
LT (1) | LT3110849T (ru) |
MX (1) | MX2016011155A (ru) |
RS (1) | RS61129B1 (ru) |
SG (2) | SG11201607104RA (ru) |
SI (1) | SI3110849T1 (ru) |
WO (1) | WO2015130173A1 (ru) |
ZA (2) | ZA201605770B (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459212B (zh) | 2014-02-28 | 2021-07-13 | 美勒斯公司 | 结合erbb-2和erbb-3的抗体 |
EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
KR20180030856A (ko) | 2015-07-10 | 2018-03-26 | 메뤼스 엔.페. | 인간 cd3 결합 항체 |
CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
CA2949032A1 (en) * | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Site specific her2 antibody drug conjugates |
WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
ITUA20162242A1 (it) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | Un nuovo anticorpo anti-erbb2 |
WO2018182420A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
EP3600413A1 (en) * | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
AU2018246872C1 (en) * | 2017-03-31 | 2023-05-18 | Merus N.V. | ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour |
EP3625264B9 (en) * | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
SG11202000054RA (en) * | 2017-07-06 | 2020-02-27 | Merus Nv | Bispecific anti pd1-anti tim3 antibodies |
BR112020002695A2 (pt) | 2017-08-09 | 2020-08-25 | Merus N.V. | anticorpos que se ligam à egfr e cmet |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
JP2021519610A (ja) | 2018-03-30 | 2021-08-12 | メルス ナムローゼ フェンノートシャップ | 多価抗体 |
US20220380440A1 (en) * | 2018-12-31 | 2022-12-01 | Merus N.V. | Truncated multivalent multimers |
AU2020222749A1 (en) | 2019-02-14 | 2021-09-02 | Merus N.V. | Combinations of binding moieties that bind EGFR, HER2 and HER3. |
US20220372166A1 (en) | 2019-10-24 | 2022-11-24 | Merus N.V. | Means and methods for treating subjects with her2 and her3 positive cancer |
US20240026029A1 (en) | 2020-11-04 | 2024-01-25 | Merus N.V. | Means and methods for treating subjects with erbb3 mutation positive cancer |
JP2024506416A (ja) | 2020-12-18 | 2024-02-13 | メルス・ナムローゼ・フェンノートシャップ | 抗体組成物 |
WO2024030027A1 (en) | 2022-08-05 | 2024-02-08 | Merus N.V. | Means and methods for treating castration-resistant prostate cancer |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
KR100255717B1 (ko) | 1991-07-15 | 2000-05-01 | 그레이엄 브레레톤 | 항체의 생산방법 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
CN100457914C (zh) | 1999-04-15 | 2009-02-04 | 荷兰克鲁塞尔公司 | 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白 |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
DK1829971T3 (da) | 2001-07-04 | 2010-08-16 | Chromagenics Bv | DNA-sekvenser med anti-repressoraktivitet |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | INTERACTION PREDICTION DEVICE |
CN100480260C (zh) | 2002-07-18 | 2009-04-22 | 克鲁塞尔荷兰公司 | 抗体混合物的重组生产 |
SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
AU2004251890B2 (en) | 2003-06-25 | 2010-09-23 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
EA010350B1 (ru) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Антитела против cd3 и способы их применения |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
AU2007353412A1 (en) | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
JP5564266B2 (ja) | 2007-02-16 | 2014-07-30 | メリマック ファーマシューティカルズ インコーポレーティッド | Erbb3に対する抗体およびその使用 |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
WO2009005809A2 (en) | 2007-07-02 | 2009-01-08 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
WO2009086197A1 (en) | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
ES2774337T3 (es) | 2008-01-07 | 2020-07-20 | Amgen Inc | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
CA2715043C (en) | 2008-02-05 | 2021-02-16 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
KR102261586B1 (ko) | 2008-06-27 | 2021-06-08 | 메뤼스 엔.페. | 항체 생산 비-인간 포유동물 |
CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
JP5746051B2 (ja) | 2009-01-15 | 2015-07-08 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Her−3の測定による患者の反応を判定する方法 |
US20120020952A1 (en) | 2009-01-26 | 2012-01-26 | Genmab A/S | Methods for producing mixtures of antibodies |
CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
KR102010827B1 (ko) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
JP5960598B2 (ja) * | 2009-11-04 | 2016-08-02 | アフィボディ・アーベー | Her3結合ポリペプチド |
US20130185821A1 (en) * | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
AU2011213585B2 (en) | 2010-02-08 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
AU2011290672B2 (en) | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
CN103429262A (zh) * | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
KR102108521B1 (ko) | 2011-03-25 | 2020-05-11 | 아이크노스 사이언스 에스. 아. | 헤테로 이량체 면역글로불린 |
ES2657862T3 (es) * | 2011-05-13 | 2018-03-07 | Gamamabs Pharma | Anticuerpos contra HER3 |
CN103781800A (zh) * | 2011-06-20 | 2014-05-07 | 协和发酵麒麟株式会社 | 抗erbB3抗体 |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
IN2014CN03042A (ru) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
ES2745684T3 (es) * | 2011-11-23 | 2020-03-03 | Medimmune Llc | Moléculas de unión específicas para HER3 y usos de las mismas |
AU2012349735B2 (en) * | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
CN104093742A (zh) | 2011-12-05 | 2014-10-08 | 诺华股份有限公司 | 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体 |
CN102448183A (zh) | 2012-01-18 | 2012-05-09 | 大唐移动通信设备有限公司 | 一种Uu接口重配置方法及设备 |
EP2823270B1 (en) | 2012-03-09 | 2022-05-04 | Promega Corporation | pH SENSORS |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
NZ630551A (en) | 2012-04-20 | 2017-11-24 | Merus Nv | Methods and means for the production of ig-like molecules |
SI2900694T1 (sl) | 2012-09-27 | 2018-12-31 | Merus N.V. | Bispecifična IGG protitelesa kot vključitelji T-celic |
AU2013331763B2 (en) * | 2012-10-15 | 2018-02-15 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
US20160319034A1 (en) | 2013-03-14 | 2016-11-03 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
CN105264382A (zh) | 2013-04-05 | 2016-01-20 | 美国控股实验室公司 | 基于检测her3活化辅助癌症的诊断、预后和治疗的***和方法 |
US10239951B2 (en) | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
CN106459212B (zh) | 2014-02-28 | 2021-07-13 | 美勒斯公司 | 结合erbb-2和erbb-3的抗体 |
-
2015
- 2015-02-27 CN CN201580017328.7A patent/CN106459212B/zh active Active
- 2015-02-27 IL IL301147A patent/IL301147A/en unknown
- 2015-02-27 LT LTEP15708907.9T patent/LT3110849T/lt unknown
- 2015-02-27 ES ES18194847T patent/ES2826774T3/es active Active
- 2015-02-27 EP EP18194847.2A patent/EP3470435B1/en active Active
- 2015-02-27 EP EP15708907.9A patent/EP3110849B9/en active Active
- 2015-02-27 AU AU2015223567A patent/AU2015223567B2/en active Active
- 2015-02-27 DK DK15708907.9T patent/DK3110849T3/da active
- 2015-02-27 SG SG11201607104RA patent/SG11201607104RA/en unknown
- 2015-02-27 MX MX2016011155A patent/MX2016011155A/es unknown
- 2015-02-27 CA CA2941077A patent/CA2941077A1/en active Pending
- 2015-02-27 SG SG10201913289TA patent/SG10201913289TA/en unknown
- 2015-02-27 KR KR1020167026645A patent/KR20160145560A/ko not_active IP Right Cessation
- 2015-02-27 US US15/121,623 patent/US11279770B2/en active Active
- 2015-02-27 EA EA201691438A patent/EA201691438A1/ru unknown
- 2015-02-27 EP EP20191815.8A patent/EP3805268A1/en active Pending
- 2015-02-27 HU HUE15708907A patent/HUE052506T2/hu unknown
- 2015-02-27 JP JP2016554189A patent/JP6967853B2/ja active Active
- 2015-02-27 ES ES15708907T patent/ES2833599T3/es active Active
- 2015-02-27 WO PCT/NL2015/050125 patent/WO2015130173A1/en active Application Filing
- 2015-02-27 KR KR1020247009115A patent/KR20240042540A/ko unknown
- 2015-02-27 SI SI201531419T patent/SI3110849T1/sl unknown
- 2015-02-27 RS RS20201418A patent/RS61129B1/sr unknown
-
2016
- 2016-08-18 ZA ZA2016/05770A patent/ZA201605770B/en unknown
- 2016-08-25 CL CL2016002156A patent/CL2016002156A1/es unknown
- 2016-08-28 IL IL247520A patent/IL247520B2/en unknown
-
2020
- 2020-01-23 JP JP2020009321A patent/JP7358256B2/ja active Active
- 2020-11-19 HR HRP20201837TT patent/HRP20201837T1/hr unknown
- 2020-11-24 CY CY20201101108T patent/CY1123556T1/el unknown
- 2020-12-08 AU AU2020286212A patent/AU2020286212A1/en not_active Abandoned
-
2021
- 2021-08-18 ZA ZA2021/05920A patent/ZA202105920B/en unknown
-
2022
- 2022-02-18 US US17/675,431 patent/US20220348683A1/en active Pending
- 2022-03-01 JP JP2022030934A patent/JP2022071071A/ja active Pending
- 2022-10-19 US US18/047,933 patent/US20230242669A1/en active Pending
-
2024
- 2024-01-22 US US18/419,527 patent/US20240158532A1/en active Pending
- 2024-01-22 US US18/419,492 patent/US20240158531A1/en active Pending
- 2024-04-01 JP JP2024058922A patent/JP2024079823A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201501063A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
EA201591973A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201792590A1 (ru) | КОНЪЮГАТ АНТИТЕЛА ПРОТИВ ErbB2 И ЛЕКАРСТВЕННОГО СРЕДСТВА И ЕГО КОМПОЗИЦИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ | |
EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
EA201890082A1 (ru) | Эпитоп антитела | |
EA201892440A1 (ru) | Антитела к tl1a и их применения | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка |